Atomoxetine hydrohloride oral suspension - OWP Pharmaceuticals
Alternative Names: Atomoxetine - OWP PharmaceuticalsLatest Information Update: 28 Aug 2026
At a glance
- Originator OWP Pharmaceuticals
- Class Behavioural disorder therapies; Propylamines
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for clinical-Phase-Unknown development in Attention-deficit-hyperactivity-disorder in USA (PO, Suspension)
- 12 Jul 2023 Clinical trials in Attention-deficit hyperactivity disorder in USA (PO) before July 2023 (OWP Pharmaceuticals pipeline, July 2023)
- 17 Nov 2021 Preclinical trials in Attention-deficit hyperactivity disorder in USA (PO) (OWP Pharmaceuticals).